A clinical evaluation of resorbable hydroxylapatite for the repair of human intra-osseous defects.
One of the goals of periodontal therapy is actual hard- and soft-tissue regeneration or at least the functional repair of periodontal defects. Alloplastic materials used in the past included dense hydroxylapatite grafts which were non-resorbable and often exfoliated. A new resorbable hydroxylapatite biomaterial [OsteoGen (HA RESORB)] was used during flap surgery. After the usual initial therapy, full-thickness flaps were elevated. A through debridement of the roots and osseous defects was accomplished. The defects were measured and then filled with OsteoGen. The mean initial bone defect depth was 4.47 mm. These defects were re-evaluated by the probing of bone levels after a 4-6-month healing period. A mean of 2.26 mm of new bone fill was obtained. This represents an average fill of 51%. Seventeen of the 22 defects had 42% or more actual new bone fill. No foreign body reaction or exfoliation occurred.
Corsair
A
A
D016301:Alveolar Bone Loss / Q000601:surgery*; D001673:Biodegradation, Environmental; D015921:Dental Implants; D017886:Durapatite; D006801:Humans; D006882:Hydroxyapatites / Q000627:therapeutic use*; D010510:Periodontal Diseases / Q000601:surgery*; D013524:Surgical Flaps
D015921:Dental Implants; D006882:Hydroxyapatites; D017886:Durapatite